Publications - IR Sant Pau

Search

27/10/2023 Frontline therapy in Chronic Lymphocytic Leukemia

Arguello-Tomas, M, Albiol, N, Moreno, C. Frontline therapy in Chronic Lymphocytic Leukemia. ACTA HAEMATOLOGICA. 2023; 147(1)DOI:10.1159/000534730. PMID:37899041. IF:1.700(Q3/8D).

21/10/2023 Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Socié G., Barba P., Barlev A., Sanz J., García-Cadenas I., Chevallier P., Fagioli F., Guzman-Becerra N., Kumar D., Ljungman P., Pigneux A., Sadetsky N., Yáñez San Segundo L., Shadman M., Storek J., Thirumalai D., Xing B., Mohty M.. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. BONE MARROW TRANSPLANTATION. 2023; 59(1)DOI:10.1038/s41409-023-02127-9. PMID:37865719. IF:4.500(Q1/2D).

01/10/2023 Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Piñana, JL, Heras, I, Aiello, TF, García-Cadenas, I, Vazquez, L, Lopez-Jimenez, J, Chorao, P, Aroca, C, García-Vidal, C, Arroyo, I, Soler-Espejo, E, López-Corral, L, Avendaño-Pita, A, Arrufat, A, Garcia-Gutierrez, V, Arellano, E, Hernández-Medina, L, González-Santillana, C, Morell, J, Hernández-Rivas, JA, Rodriguez-Galvez, P, Mico-Cerdá, M, Guerreiro, M, Campos, D, Navarro, D, Cedillo, A, Martino, R, Solano, C. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses-Basel. 2023; 15(10)DOI:10.3390/v15102066. PMID:37896843. IF:3.800(Q2/5D).

01/09/2023 mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect

Albiol, N, Lynton-Pons, E, Aso, O, Moga, E, Vidal, S, Gomez-Perez, L, Santiago, JA, Triquell, M, Roch, N, Lazaro, E, Gonzalez, I, Lopez-Contreras, J, Esquirol, A, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. LEUKEMIA RESEARCH. 2023; 132DOI:10.1016/j.leukres.2023.107347. PMID:37356281. IF:2.100(Q3/6D).

16/08/2023 Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances

Pinana, JL, Perez, A, Chorao, P, Guerreiro, M, Garcia-Cadenas, I, Solano, C, Martino, R, Navarro, D. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. Transplant Infectious Disease. 2023; DOI:10.1111/tid.14117. PMID:37585370. IF:2.600(Q2/5D).

15/08/2023 B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Woyach, JA, Ghia, P, Byrd, JC, Ahn, IE, Moreno, C, O'Brien, SM, Jones, D, Cheung, LWK, Chong, ELZB, Kwei, K, Dean, JP, James, DF, Wiestner, A. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. CLINICAL CANCER RESEARCH. 2023; 29(16)DOI:10.1158/1078-0432.CCR-22-3887. PMID:37314786. IF:10.400(Q1/1D).

02/08/2023 Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience

Fernandez-Sojo J., Valdivia E., Esquirol A., Portos, JM, Rovira M., Suarez M., Diaz-de-Heredia C., Uria, ML, Ortí G., Ferra C., Mussetti A., Paviglianiti A., Marsal J., Badell I., Lozano M., Gomez D., Azqueta C., Martorell L., Rubio N., Garcia-Buendia A., Villa J., Carreras E., Querol S.. Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience. VOX SANGUINIS. 2023; 118(9)DOI:10.1111/vox.13499. PMID:37533171. IF:1.800(Q3/7D).

20/07/2023 Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Munir, T, Moreno, C, Owen, C, Follows, G, Benjamini, O, Janssens, A, Levin, MD, Osterborg, A, Robak, T, Simkovic, M, Stevens, D, Voloshin, S, Vorobyev, V, Yagci, M, Ysebaert, L, Qi, KQ, Qi, QY, Parisi, L, Srinivasan, S, Schuier, N, Baeten, K, Howes, A, Caces, DB, Niemann, CU, Kater, AP. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(21)DOI:10.1200/JCO.22.02283. PMID:37279408. IF:42.100(Q1/1D).

06/07/2023 Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center

Arguello-Tomas M., Albiol N., Jara P., Garcia-Cadenas I., Redondo S., Esquirol A., Novelli S., Saavedra S., Martino R., Nomdedeu J., Sierra J., Mora A., Moreno C.. Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center. LEUKEMIA & LYMPHOMA. 2023; 64(10)DOI:10.1080/10428194.2023.2232489. PMID:37452739. IF:2.200(Q3/6D).

01/07/2023 Detection of cytomegalovirus in bronchoalveolar lavage fluid from immunocompromised patients with pneumonitis by viral culture and DNA quantification

Berengua, C, Miro, E, Gutierrez, C, Sanchez, M, Mulero, A, Ramos, P, del Cuerpo, M, Torrego, A, Garcia-Cadenas, I, Pajares, V, Navarro, F, Martino, R, Rabella, N. Detection of cytomegalovirus in bronchoalveolar lavage fluid from immunocompromised patients with pneumonitis by viral culture and DNA quantification. JOURNAL OF VIROLOGICAL METHODS. 2023; 317DOI:10.1016/j.jviromet.2023.114743. PMID:37116585. IF:2.200(Q3/7D).

01/07/2023 Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature

Garcia-Cadenas, I, Redondo, S, Esquirol, A, Portos, JM, Novelli, S, Saavedra, S, Moreno, C, Garrido, A, Onate, G, Lopez, J, Caballero, AC, Miqueleiz, S, Arguello-Tomas, M, Briones, J, Sierra, J, Martino, R. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature. Transplantation And Cellular Therapy. 2023; 29(7)DOI:10.1016/j.jtct.2023.04.008. PMID:37086849. IF:3.600(Q1/3D).

01/06/2023 Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation

Coll, CF, de la Fe, MM, Garcia, LP, Vaz, CP, Fernando, MIH, Almorox, RB, Garcia-Cadenas, I, Munoz, MC, Ripa, TZ, Al-Sibai, JZ, Novoa, S, Aguado, B, Catarineu, AT, Lopez-Godino, O, Bofarull, RM, Kwon, M, Campos, A, Barrigon, DC, Santasusana, JMR. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY. 2023; 110(6)DOI:10.1111/ejh.13947. PMID:36813736. IF:2.300(Q2/5D).

05/05/2023 Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Onate, G, Pratcorona M., Garrido A., Artigas-Baleri A., Bataller A., Tormo M., Arnan M., Vives S., Coll R., Salamero O., Vall-Llovera F., Sampol A., Garcia A., Cervera M., Avila S.G., Bargay J., Ortín X., Nomdedéu J.F., Esteve J., Sierra J.. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer Journal. 2023; 13(1)DOI:10.1038/s41408-023-00839-1. PMID:37147301. IF:12.900(Q1/1D).

01/05/2023 SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

Pinana, JL, Martino, R, Vazquez, L, Lopez-Corral, L, Perez, A, Chorao, P, Avendano-Pita, A, Pascual, MJ, Sanchez-Salinas, A, Sanz-Linares, G, Olave, MT, Arroyo, I, Tormo, M, Villalon, L, Conesa-Garcia, V, Gago, B, Terol, MJ, Villalba, M, Garcia-Gutierrez, V, Cabero, A, Hernandez-Rivas, JA, Ferrer, E, Garcia-Cadenas, I, Teruel, A, Navarro, D, Cedillo, A, Sureda, A, Solano, C. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. BONE MARROW TRANSPLANTATION. 2023; 58(5)DOI:10.1038/s41409-023-01946-0. PMID:36854892. IF:4.500(Q1/2D).

20/04/2023 Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC.

Velao, SR, Cadenas, IG, Cuesta, MA, Sanchez-Ortega, I, Fernandez-Aviles, F, Roldan, E, Torrent, A, Viguria, MC, Villar, S, Bento, L, Yanez, L, Martino, R, Pinana, JL. Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC.. ACTA HAEMATOLOGICA. 2023; 146(2)DOI:10.1159/000528242. PMID:36446336. IF:1.700(Q3/8D).

19/04/2023 Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Mar, 10.1038/s41409-023-01949-x, 2023)

Mussetti, A, Bento, L, Bastos-Oreiro, M, Rius-Sansalvador, B, Albo, C, Bailen, R, Barba, P, Benzaquen, A, Briones, J, Caballero, AC, Campos, A, Espanol, I, Ferra, C, Lopez, SG, Sierra, PAG, Guerra, LM, Hernani, R, Iacoboni, G, Jimenez-Ubieto, A, Kwon, M, Corral, LL, Lopez-Godino, O, Munoz, MCM, Martinez-Cibrian, N, Gomez, JM, Perez-Ortega, L, Orti, G, Ortiz-Maldonado, V, Pascual, MJ, Perera, M, Perez, A, Reguera, JL, Sanchez, JM, Sanz, J, Torrent, A, Yanez, L, Varela, R, Echechipia, IC, Caballero, D, Sureda, A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Mar, 10.1038/s41409-023-01949-x, 2023). BONE MARROW TRANSPLANTATION. 2023; 58(6)DOI:10.1038/s41409-023-01967-9. PMID:37076611. IF:4.500(Q1/2D).

17/04/2023 Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Crees, ZD, Rettig, MP, Jayasinghe, RG, Stockerl-Goldstein, K, Larson, SM, Arpad, I, Milone, GA, Martino, M, Stiff, P, Sborov, D, Pereira, D, Micallef, I, Moreno-Jimenez, G, Mikala, G, Coronel, MLP, Holtick, U, Hiemenz, J, Qazilbash, MH, Hardy, N, Latif, T, Garcia-Cadenas, I, Vainstein-Haras, A, Sorani, E, Gliko-Kabir, I, Goldstein, I, Ickowicz, D, Shemesh-Darvish, L, Kadosh, S, Gao, F, Schroeder, MA, Vij, R, DiPersio, JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. NATURE MEDICINE. 2023; 29(4)DOI:10.1038/s41591-023-02273-z. PMID:37069359. IF:58.700(Q1/1D).

01/04/2023 Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

Perl A.E., Larson R.A., Podoltsev N.A., Strickland S., Wang E.S., Atallah E., Schiller G.J., Martinelli G., Neubauer A., Sierra J., Montesinos P., Recher C., Yoon S.-S., Maeda Y., Hosono N., Onozawa M., Kato T., Kim H.-J., Hasabou N., Nuthethi R., Tiu R., Levis M.J.. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy. 2023; 29(4)DOI:10.1016/j.jtct.2022.12.006. PMID:36526260. IF:3.600(Q1/3D).

01/04/2023 Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism

Martin-Fernandez, L, Garcia-Martinez, I, Lopez, S, Martinez-Perez, A, Vilalta, N, Plaza, M, Moret, C, Vinuela, A, Brown, AA, Panousis, NI, Buil, A, Dermitzakis, ET, Corrales, I, Souto, JC, Vidal, F, Soria, JM. Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism. THROMBOSIS AND HAEMOSTASIS. 2023; 123(04)DOI:10.1055/s-0043-1760844. PMID:36696913. IF:5.000(Q1/2D).

14/03/2023 Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Mussetti, A, Bento, L, Bastos-Oreiro, M, Sansalvador, BR, Albo, C, Bailen, R, Barba, P, Benzaquen, A, Briones, J, Caballero, AC, Campos, A, Espanol, I, Ferra, C, Lopez, SG, Sierra, PAG, Guerra, LM, Hernani, R, Iacoboni, G, Ubieto, AIJ, Kwon, M, Corral, LL, Lopez-Godino, O, Munoz, MCM, Martinez-Cibrian, N, Gomez, JM, Perez-Ortega, L, Ortf, G, Ortiz-Maldonado, V, Pascual, MJ, Perera, M, Perez, A, Reguera, JL, Sanchez, JM, Sanz, J, Torrent, A, Yanez, L, Varela, R, Echechipia, IC, Caballero, D, Sureda, A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. BONE MARROW TRANSPLANTATION. 2023; 58(6)DOI:10.1038/s41409-023-01949-x. PMID:36918682. IF:4.500(Q1/2D).

01/03/2023 T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo

Nunez, Y, Garcia-Leon, A, Falgas, A, Serna, N, Sanchez-Garcia, L, Garrido, A, Sierra, J, Gallardo, A, Unzueta, U, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. Pharmaceutics. 2023; 15(3)DOI:10.3390/pharmaceutics15030727. PMID:36986589. IF:4.900(Q1/2D).

01/03/2023 Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts

Berengua, C, Martino, R. Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts. Hemato. 2023; 4(1)DOI:10.3390/hemato4010008. PMID:. IF:(Q/D).

05/01/2023 One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Pinana, JL, Vazquez, L, Calabuig, M, Lopez-Corral, L, Martin-Martin, G, Villalon, L, Sanz-Linares, G, Conesa-Garcia, V, Sanchez-Salinas, A, Gago, B, Facal, A, Risco-Galvez, I, Olave, MT, Espigado, I, Lopez-Jimenez, J, Hernandez-Rivas, JA, Avendano-Pita, A, Arroyo, I, Ferrer, E, Garcia-Cadenas, I, Gonzalez-Santillana, C, Roldan-Perez, A, Ferrer, B, Guerreiro, M, Suarez-Lledo, M, Camara, A, Campos-Beltran, D, Navarro, D, Cedillo, A, Sureda, A, Solano, C, Martino, R. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer Journal. 2023; 13(1)DOI:10.1038/s41408-022-00778-3. PMID:36599843. IF:12.900(Q1/1D).

01/01/2023 Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

Barba, P, Morgades, M, Montesinos, P, Gonzalez-Campos, J, Torrent, A, Gil, C, Bernal, T, Tormo, M, Mercadal, S, Novoa, S, Garcia-Cadenas, I, de Llano, MPQ, Cervera, M, Coll, R, Bermudez, A, Amigo, ML, Monsalvo, S, Esteve, J, Garcia-Boyero, R, Novo, A, Rivas, JMH, Cladera, A, Martinez-Sanchez, P, Serrano, J, Artola, MT, Soria, B, Abella, E, Vall-Llovera, F, Bergua, J, Herrera, P, Barrios, D, Ribera, JM. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000810. PMID:36583094. IF:11.900(Q1/1D).

01/01/2023 High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023)

Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023). CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00564-0. PMID:36460806. IF:4.800(Q1/2D).

01/01/2023 LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

Cruz D., Rodríguez-Romanos R., González-Bartulos M., García-Cadenas I., de la Cámara R., Heras I., Buño I., Santos N., Lloveras N., Velarde P., Tuset E., Martínez C., González M., Sanz G.F., Ferrá C., Sampol A., Coll R., Pérez-Simón J.A., López-Jiménez J., Jurado M., Gallardo D.. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1066393. PMID:36742309. IF:5.700(Q1/3D).

01/01/2023 Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Kwon M., Iacoboni G., Reguera J.L., López Corral L., Morales R.H., Ortiz-Maldonado V., Guerreiro M., Caballero A.C., Domínguez M.L.G., Pina J.M.S., Mussetti A., Sancho J.M., Bastos-Oreiro M., Catala E., Delgado J., Henriquez H.L., Sanz J., Calbacho M., Bailén R., Carpio C., Ribera J.M., Sureda A., Briones J., Hernandez-Boluda J.C., Cebrián N.M., Martin J.L.D., Martín A., Barba P.. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. HAEMATOLOGICA. 2023; 108(1)DOI:10.3324/haematol.2022.280805. PMID:35770532. IF:10.100(Q1/2D).

01/01/2023 Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Moia R., Dondolin R., De Propris M.S., Talotta D., Mouhssine S., Perutelli F., Reda G., Mattiello V., Rigolin G.M., Motta M., Olivieri J., Fanin R., Perbellini O., Ferrarini I., Mauro F.R., Del Giudice I., Laurenti L., Tomasso A., Gentile M., Frustaci A.M., Tedeschi A., Gozzetti A., Stelitano C., Visco C., Moreno C., Forconi F., Marasca R., Coscia M., Rossi D., Foà R., Gaidano G.. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. HEMATOLOGICAL ONCOLOGY. 2023; 41(3)DOI:10.1002/hon.3080. PMID:36190298. IF:3.300(Q2/4D).

01/01/2023 A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Dickinson M.J., Barba P., Jäger U., Shah N.N., Blaise D., Briones J., Shune L., Boissel N., Bondanza A., Mariconti L., Marchal A.-L., Quinn D.S., Yang J., Price A., Sohoni A., Treanor L.M., Orlando E.J., Mataraza J., Davis J., Lu D., Zhu X., Engels B., Moutouh-de Parseval L., Brogdon J.L., Moschetta M., Flinn I.W.. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery. 2023; 13(9)DOI:10.1158/2159-8290.CD-22-1276. PMID:37249512. IF:30.600(Q1/1D).

01/01/2023 Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study

Solano C., Castro-Rebollo P., Pérez-Martínez A., López-Corral L., Barba-Suñol P., Kwon M., Ortiz V., Sanz-Caballer J., Caballero A.C., Martínez J., Cedillo Á., Sureda A.. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study. BMJ Open. 2023; 13(7)DOI:10.1136/bmjopen-2022-071371. PMID:37491085. IF:2.400(Q1/3D).

01/01/2023 A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Muñoz A., Ay C., Grilz E., López S., Font C., Pachón V., Castellón V., Martínez-Marín V., Salgado M., Martínez E., Calzas J., Ortega L., Rupérez A., Salas E., Pabinger I., Soria J.M.. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(16)DOI:10.1200/JCO.22.00255. PMID:36730884. IF:42.100(Q1/1D).

01/01/2023 Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

Bailén R., Alenda R., Herruzo-Delgado B., Acosta-Fleitas C., Vallés A., Esquirol A., Fonseca M., Solán L., Sánchez-Vadillo I., Bautista G., Bento L., López-Godino O., Pérez-Martínez A., Torrent A., Zanabili J., Calbacho M., Moreno M.Á., Pascual-Cascón M.J., Guerra-Domínguez L., Chinea A., García-Cadenas I., López-Corral L., Boix-Giner F., López Lorenzo J.L., Humala K., Duarte R., Sampol A., Heras I., Vicario J.L., Balas A., Oarbeascoa G., Fernández-Caldas P., Anguita J., Kwon M.. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1165759. PMID:37304258. IF:5.700(Q1/3D).

01/01/2023 Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies

García-Calderón C.B., Sierro-Martínez B., García-Guerrero E., Sanoja-Flores L., Muñoz-García R., Ruiz-Maldonado V., Jimenez-Leon M.R., Delgado-Serrano J., Molinos-Quintana Á., Guijarro-Albaladejo B., Carrasco-Brocal I., Lucena J.-M., García-Lozano J.-R., Blázquez-Goñi C., Reguera-Ortega J.L., González-Escribano M.-F., Reinoso-Segura M., Briones J., Pérez-Simón J.A., Caballero-Velázquez T.. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1152498. PMID:37122702. IF:5.700(Q1/3D).

01/12/2022 mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients (Nov, 10.1007/s00520-022-07376-w, 2022)

Albiol, N, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients (Nov, 10.1007/s00520-022-07376-w, 2022). SUPPORTIVE CARE IN CANCER. 2022; 30(12)DOI:10.1007/s00520-022-07452-1. PMID:36400980. IF:3.100(Q1/3D).

01/10/2022 Identification of Two Eosinophil Subsets in Induced Sputum from Patients with Allergic Asthma According to CD15 and CD66b Expression

Curto, E, Mateus-Medina, EF, Crespo-Lessmann, A, Osuna-Gomez, R, Ujaldon-Miro, C, Garcia-Moral, A, Galvan-Blasco, P, Soto-Retes, L, Ramos-Barbon, D, Plaza, V. Identification of Two Eosinophil Subsets in Induced Sputum from Patients with Allergic Asthma According to CD15 and CD66b Expression. International Journal of Environmental Research and Public Health. 2022; 19(20)DOI:10.3390/ijerph192013400. PMID:36293979. IF:4.614(Q1/3D).

01/10/2022 Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

Saliba, RM, Alousi, AM, Pidala, J, Arora, M, Spellman, SR, Hemmer, MT, Wang, T, Abboud, C, Ahmed, S, Antin, JH, Beitinjaneh, A, Buchbinder, D, Byrne, M, Cahn, JY, Choe, H, Hanna, R, Hematti, P, Kamble, RT, Kitko, CL, Laughlin, M, Lekakis, L, MacMillan, ML, Martino, R, Mehta, PA, Nishihori, T, Patel, SS, Perales, MA, Rangarajan, HG, Ringden, O, Rosenthal, J, Savani, BN, Schultz, KR, Seo, S, Teshima, T, van der Poel, M, Verdonck, LF, Weisdorf, D, Wirk, B, Yared, JA, Schriber, J, Champlin, RE, Ciurea, SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation And Cellular Therapy. 2022; 28(10)DOI:10.1016/j.jtct.2022.07.013. PMID:35853610. IF:3.200(Q2/5D).

22/09/2022 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Dohner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Rollig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Lowenberg, B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. BLOOD. 2022; 140(12)DOI:10.1182/blood.2022016867. PMID:35797463. IF:20.300(Q1/1D).

15/09/2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, Wang, SA, Bagg, A, Barbui, T, Branford, S, Bueso-Ramos, CE, Cortes, JE, Dal Cin, P, DiNardo, CD, Dombret, H, Duncavage, EJ, Ebert, BL, Estey, EH, Facchetti, F, Foucar, K, Gangat, N, Gianelli, U, Godley, LA, Gokbuget, N, Gotlib, J, Hellstrom-Lindberg, E, Hobbs, GS, Hoffman, R, Jabbour, EJ, Kiladjian, JJ, Larson, RA, Le Beau, MM, Loh, MLC, Lowenberg, B, Macintyre, E, Malcovati, L, Mullighan, CG, Niemeyer, C, Odenike, OM, Ogawa, S, Orfao, A, Papaemmanuil, E, Passamonti, F, Porkka, K, Pui, CH, Radich, JP, Reiter, A, Rozman, M, Rudelius, M, Savona, MR, Schiffer, CA, Schmitt-Graeff, A, Shimamura, A, Sierra, J, Stock, WA, Stone, RM, Tallman, MS, Thiele, J, Tien, HF, Tzankov, A, Vannucchi, AM, Vyas, P, Wei, AH, Weinberg, OK, Wierzbowska, A, Cazzola, M, Dohner, H, Tefferi, A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. BLOOD. 2022; 140(11)DOI:10.1182/blood.2022015850. PMID:35767897. IF:20.300(Q1/1D).

01/05/2022 An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022)

Jimenez, AJM, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022). BONE MARROW TRANSPLANTATION. 2022; 57(5)DOI:10.1038/s41409-022-01625-6. PMID:35297406. IF:4.800(Q1/2D).

01/01/2022 CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center

Arguello-Tomas M., Albiol N., Jara P., Sierra J., Mora A., Moreno C.. CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01349-0. PMID:36163896. IF:(Q/D).